AGENUS INC
AGEN evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for AGEN—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · AGEN
Agenus Inc. is a clinical-stage biotechnology company developing immuno-oncology therapies, including antibodies, cell therapies, and vaccine adjuvants, with a lead focus on the BOT/BAL combination for colorectal cancer.
Key risk: Capital requirement risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 3 pipeline candidates · 13 clinical trials for AGENUS INC.
Agenus Inc. is a clinical-stage biotechnology company developing immuno-oncology therapies, including antibodies, cell therapies, and vaccine adjuvants, with a lead focus on the BOT/BAL combination for colorectal cancer.
- Lead product candidates are botensilimab (BOT), a CTLA-4 blocking antibody, and balstilimab (BAL), a PD-1 blocking antibody, being developed for colorectal and other cancers [sec_mda · as of 2026-08-07].
- Cash and equivalents were $18.7M as of 2026-06-30, with total debt of $60.1M and negative shareholders' equity of -$326.4M [sec].
- The company closed a strategic collaboration with Zydus Lifesciences Ltd. in 2026, receiving a $20M escrow payment for clinical supply [sec_mda · as of 2026-08-07].
- Agenus maintains multiple discovery platforms, including antibody discovery, a saponin-based vaccine adjuvant (STIMULON cpcQS-21), and allogeneic iNKT cell therapies [sec_mda · as of 2026-08-07].
- The company has faced challenges including an FDA recommendation against an accelerated approval path for BOT+BAL in MSS mCRC, requiring a larger Phase 3 trial [sec · filed 2026-04-30].
What works
- Strategic collaboration with Zydus Lifesciences provides manufacturing flexibility and a $20M escrow payment for clinical supply [sec_mda · as of 2026-08-07].
- Diverse pipeline includes multiple platforms (antibody, vaccine adjuvant, iNKT cell therapies) that support future candidate generation [sec_mda · as of 2026-08-07].
- The company has resolved the SEC investigation and a related securities class action, reducing legal overhang [sec_mda · as of 2026-08-07].
- Physician engagement is expanding through regulatory-authorized access pathways and an exclusive global access distribution partner [sec_mda · as of 2026-08-07].
What to weigh
- Cash runway is limited; the company states it will require additional capital to fund its registration and commercialization strategy and achieve profitability [sec_mda · as of 2026-03-16].
- The FDA recommended against an accelerated approval path for BOT+BAL in MSS mCRC, forcing a larger, more expensive Phase 3 trial [sec · filed 2026-04-30].
- Substantially all outstanding stock options are deeply underwater due to a depressed stock price, indicating market skepticism [sec · filed 2026-04-30].
- The company has negative shareholders' equity of -$326.4M as of 2026-06-30, reflecting accumulated losses [sec].
From the filings
Quoted directly from source documents.
Lead assets are botensilimab and balstilimab for colorectal cancer
“Our strategy is to focus capital on execution of programs that we believe have the clearest path to meaningful clinical and commercial value, led by BOT/BAL in colorectal and colon cancer and selected other tumor types.”
SEC MD&A · August 7, 2026
Need for additional capital
“To advance our planned registration and commercialization strategy for botensilimab/balstilimab, and fund the Company through achievement of profitability, we will require additional capital infusions.”
SEC MD&A · March 16, 2026
Risks & what to watch (4)›
Key risks
- Capital requirement risk — The company needs additional capital to fund registration and commercialization; cash is only $18.7M as of 2026-06-30 [sec_mda · as of 2026-03-16].
- Regulatory delay risk — FDA recommended against accelerated approval for BOT+BAL in MSS mCRC, requiring a large Phase 3 trial and delaying potential revenue [sec · filed 2026-04-30].
- Negative equity risk — Shareholders' equity is -$326.4M as of 2026-06-30, indicating accumulated deficits exceed assets [sec].
- Stock option overhang — Substantially all outstanding options are deeply underwater, which may affect employee retention and morale [sec · filed 2026-04-30].
What to watch
- Progress of the Phase 3 trial for BOT+BAL in MSS colorectal cancer, including enrollment and data readouts [sec · filed 2026-04-30].
- Ability to secure additional financing or strategic partnerships to extend cash runway beyond 2026 [sec_mda · as of 2026-03-16].
- Updates on regulatory submissions in the U.S. and E.U., including any conditional marketing authorization applications [sec_mda · as of 2026-05-11].
- Execution of the Zydus collaboration and delivery of clinical supply milestones [sec_mda · as of 2026-08-07].
Sources: SEC filings · SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run AGENUS INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available AGENUS INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
3.5 months
OCF -$31M
Lead: Phase 2
3 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
86
Total value held
$32.1M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 2,880,464 | $9.6M |
| vanguard portfolio management llc | 1,195,109 | $4.0M |
| marshall wace, llp | 688,203 | $2.3M |
| blackrock, inc. | 545,662 | $1.8M |
| geode capital management, llc | 348,395 | $1.2M |
| morgan stanley | 295,821 | $988K |
| renaissance technologies llc | 285,646 | $954K |
| man group plc | 278,980 | $932K |
| walleye capital llc | 241,130 | $805K |
| raymond james financial inc | 239,554 | $800K |
Showing top 10 of 86 institutional holders of AGENUS INC. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 11.2%
- Days to cover
- 8.5
- Shares short
- 4,284,092
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
AGEN short interestGovernance
Frequently asked questions
What is the AI investment thesis for AGENUS INC?
Agenus Inc. is a clinical-stage biotechnology company developing immuno-oncology therapies, including antibodies, cell therapies, and vaccine adjuvants, with a lead focus on the BOT/BAL combination for colorectal cancer.
What is AGENUS INC's lead drug candidate?
AGENUS INC's most advanced tracked candidate is agen2373 (Phase 2) for Advanced solid tumors.
Who is the CEO of AGENUS INC?
Dr. Garo H. Armen Ph.D. is the chief executive officer of AGENUS INC (AGEN).
Where is AGENUS INC headquartered?
AGENUS INC (AGEN) is headquartered in Lexington, MA, United States.
What therapeutic areas does AGENUS INC focus on?
AGENUS INC develops therapies across Oncology, Immunology, Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.